AAAAAA

   
Results: 1-7 |
Results: 7
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial
Authors: Kostler, WJ Brodowicz, T Attems, Y Hejna, M Tomek, S Amann, G Fiebiger, WCC Wiltschke, C Krainer, M Zielinski, CC
Citation: Wj. Kostler et al., Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial, ANN ONCOL, 12(9), 2001, pp. 1281-1288
Soluble ICAM-1 in breast cancer: clinical significance and biological implications
Authors: Kostler, WJ Tomek, S Brodowicz, T Budinsky, AC Flamm, M Hejna, M Krainer, M Wiltschke, C Zielinski, CC
Citation: Wj. Kostler et al., Soluble ICAM-1 in breast cancer: clinical significance and biological implications, CANCER IMMU, 50(9), 2001, pp. 483-490
Acceptance of medical information and contentment in cancer patients
Authors: Hejna, M Kostler, WJ Tomek, S Fiebiger, WCC Raderer, M Wiltschke, C Zielinski, CC
Citation: M. Hejna et al., Acceptance of medical information and contentment in cancer patients, WIEN KLIN W, 113(9), 2001, pp. 342-347
Single-agent gemcitabine as second- and third-line treatment in metastaticbreast cancer
Authors: Brodowicz, T Kostler, WJ Moslinger, R Tomek, S Vaclavik, I Herscovici, V Wiltschke, C Steger, GG Wein, W Seifert, M Kubista, E Zielinski, CC
Citation: T. Brodowicz et al., Single-agent gemcitabine as second- and third-line treatment in metastaticbreast cancer, BREAST, 9(6), 2000, pp. 338-342
Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer
Authors: Brodowicz, T Wolfram, RM Kostler, WJ Tomek, S Vaclavik, I Steger, GG Teleky, B Fugger, R Jakesz, R Zielinski, CC
Citation: T. Brodowicz et al., Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer, ANTI-CANC D, 11(8), 2000, pp. 623-628
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer
Authors: Hejna, M Kostler, WJ Raderer, M Tomek, S Brodowicz, T Scheithauer, W Wiltschke, C Zielinski, CC
Citation: M. Hejna et al., Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer, ANTI-CANC D, 11(8), 2000, pp. 629-634
Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer
Authors: Brodowicz, T Koestler, WJ Tomek, S Vaclavik, I Herscovici, V Wiltschke, C Steger, GG Zielinski, CC
Citation: T. Brodowicz et al., Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer, ANTI-CANC D, 11(3), 2000, pp. 149-153
Risultati: 1-7 |